Healthcare
Fresenius Medical Care AG & Co. KGaA(FMS)
Live Price
Offline$22.26
-0.09% today
1Y Change
-15.00%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $9.98B
- Revenue Growth
- +1.5%
- EPS Growth
- +83.6%
- Dividend Yield
- 3.9%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Fresenius Medical Care AG & Co. KGaA (FMS) is a Healthcare stock with a market cap of $9.98B and listed on NYSE. The stock last traded around $22.26 and down 15.0% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +1.5%, EPS growth of +83.6%, a dividend yield of 3.9%. What stands out right now is revenue +1.5%, EPS +83.6%, free cash flow +0.5% with operating margin 9.3% and ROIC 5.3%. The dividend matters to the case here, with a current yield around 3.9%. Valuation is more restrained than many high-expectation growth names at P/E 10.4 and price/sales 0.5. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines FMS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+1.5% vs +7.6% peer median
Operating Margin
Below sector median
+9.3% vs +19.4% peer median
P/E
Below sector median
10.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +1.5% and EPS at +83.6%, with operating margin around 9.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.9%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +4.1% | +10.2% | +3.5% |
2026 Feb 24, 2026 | +28.3% | -0.0% | +3.1% | -2.8% |
2025 Nov 4, 2025 | +8.5% | -0.2% | -1.2% | -3.0% |
Benchmark Edge
FMS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FMS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FMS Max Drawdown
-29.82%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FMS and SPY.
Company Overview
Fresenius Medical Care AG & Co. KGaA
New York Stock Exchange
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
- Leadership
- Helen Giza
- IPO Date
- Sep 17, 1996
- Employees
- 112.0k
- Street Address
- Else-KrOener Strasse 1
- Mailing
- Bad Homburg, 61352
- Region
- Bad Homburg, DE
- Reporting Currency
- USD
- Investor Line
- 49 6172 608 2522
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 10.4
- EV/EBITDA
- 5.8
- Price/Sales
- 0.5
- Price/Book
- 0.7
Growth
- Revenue
- +1.5%
- EPS
- +83.6%
- Free Cash Flow
- +0.5%
Profitability
- Gross Margin
- 25.6%
- Operating Margin
- 9.3%
- Net Margin
- 5.0%
- ROE
- 7.1%
- ROIC
- 5.3%
Balance Sheet
- Debt/Equity
- 0.76
- Current Ratio
- 1.26
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.